Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genalyte Wins $500K for Early Detection of Type 1 Diabetes

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Unique multiplexing capabilities of Maverick™ detection system could enable early detection of Type 1 diabetes and allow for potentially curative interventions.

Genalyte, Inc. has announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte’s innovative Maverick™ Detection System.

The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.

Genalyte’s novel multiplexing technology simultaneously screens for the detection of multiple auto antibodies and other proteins using a one-step, 15-minute process.

The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for Type 1 diabetes.

It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

“The pioneering work of the late Dr. Eisenbarth and others established that the development of Type 1 diabetes is an incremental process, as rogue elements of the immune system over time compromise and eventually destroy the pancreatic islet cells that produce insulin,” noted Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.

Gleeson continued, “The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible.”

Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with Type 1 diabetes.

Genalyte expects to collaborate on this phase of the project with researchers from Dr. Eisenbarth’s laboratory at the Barbara Davis Diabetes Center of the University of Colorado School of Medicine in Denver.

Dr. Gleeson added, “From early on we envisioned that the unprecedented multiplexing capabilities of our Maverick technology would make it possible to change the way that certain diseases are diagnosed and treated. We are delighted that NIDDK is supporting development of these assays that have the potential to make this goal a reality for the millions of individuals at risk of Type 1 diabetes.”

Genalyte’s Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.

The Maverick system’s one-step approach automates the washes, incubations, reagent processing and other steps needed for the analysis.

Semi-quantitative results are reported for each analyte, eliminating the need for reflex testing. The Maverick platform has a large dynamic range and excellent sensitivity, with outstanding reproducibility.

The Maverick Detection System and its ENA 4 and ENA 6 Assay Kits are currently commercially available. They simultaneously screen for several of the most common antibodies found in autoimmune connective tissue disorders, such as lupus (SLE), Sjogren’s syndrome, and scleroderma.

The assay results are highly reproducible, show excellent correlation to ELISA and are up to ten times more sensitive.

Assay kits for advanced SLE testing, rheumatoid arthritis and Type I diabetes are available under the Genalyte Technology Access program.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genalyte Signs on European Distributors as Maverick System Gains CE Mark
Mokascience, Bucher Biotec and KRD Molecular Technologies will distribute Maverick system and Genalyte multiplex assays in selected European territories.
Thursday, July 25, 2013
Next Gen Multiplexing Firm Genalyte Raises $12M Series B Financing
Maverick platform is much simpler, faster and more sensitive, flexible and cost-effective than current options.
Thursday, September 27, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!